Bayer reported a solid second quarter, with Crop Science once again emerging as the group’s strongest performer. Litigation cloud begins to liftA major focus of the earnings call was Bayer’s progress in reducing uncertainty surrounding glyphosate litigation inherited through its Monsanto acquisition. Bayer also addressed questions about Ruveon, the newly created entity housing its US glyphosate business. Leaner Bayer, but no break-up yetDespite renewed investor interest in Bayer’s structure, Anderson pushed back on suggestions that a breakup is on the cards. For several years, some shareholders have argued that Bayer’s Crop Science, Pharmaceuticals and Consumer Health businesses could command higher valuations as standalone companies rather than as part of a diversified conglomerate.